| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 4.17 Billion |
| Market Size (2030) | USD 5.56 Billion |
| CAGR (2025 - 2030) | 5.90 % |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Analysis
The Europe Glucagon-Like Peptide-1 Agonists Market size is estimated at USD 4.17 billion in 2025, and is expected to reach USD 5.56 billion by 2030, at a CAGR of 5.9% during the forecast period (2025-2030).
mainly as a result of new drug launches. Europe has approximately 57 million adults living with diabetes, and this number is expected to reach 75 million by 2026, which would represent around 10% of the total population of Europe. Europe's expenditure on diabetes is 9% of its total healthcare expenditure. Spending on diabetes largely varies among countries in Europe. It ranges from EUR 312 per capita in the Republic of Macedonia, to EUR 6,896 per capita in Norway. Similarly, the prevalence is also highly varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal. In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Trends
The dulaglutide segment occupies the highest market share in the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market in the current year
The dulaglutide segment holds the highest share in the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market in the current year and is expected to register a CAGR of about 8.3% over the forecast period.
According to the IDF, the overall diabetes expenditure in Europe among the population aged 20-79 years was USD 156 billion, and it is expected to increase to USD 174 billion by 2040. These figures indicate that approximately 9% of the total healthcare expenditure is spent on diabetes in Europe. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs.
GLP1RAs have been available internationally and are recommended when treatment escalation for type 2 diabetes is required after metformin and lifestyle management. They can be safely used with all other glucose-lowering therapies except vildagliptin. Dulaglutide (Trulicity) is a weekly subcutaneous GLP1RA that reduces HbA1c with additional weight loss and cardiorenal protection benefits. Therapy with dulaglutide allows many patients to reach and maintain target HbA1c without insulin and sulfonylureas, eliminating the associated hypoglycemia risk. GLP1RAs elicit greater weight reduction and are recommended over SLGT2 inhibitors when cerebrovascular disease other than heart failure or renal disease predominates.
The government and the companies are working towards better diabetes management. For instance, the National Service Framework (NSF) program is improving services by setting national standards to drive up service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind. Such advantages have helped the rise in the market growth.
Understand The Key Trends Shaping This Market
Download PDF
Germany is expected to register the highest CAGR in the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market over the forecast period
Germany is expected to register the highest CAGR of about 7.8% in the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market over the forecast period.
According to the German Diabetes Centre (DDZ), about 8.5 million people in Germany are affected by diabetes. The number of people with type 2 diabetes in Germany will continue to increase over the next twenty years. Diabetes is a significant health problem and one of the astounding challenges for healthcare systems all over Germany. The prevalence of known type 1 & 2 diabetes in the German adult population is very high, along with many patients not yet diagnosed with the disease. Due to an aging population and unhealthy lifestyle, the prevalence of type 2 diabetes is expected to increase steadily over the next few years. High-quality care, including adequate monitoring, control of risk factors, and active self-management, are the key factors for preventing complications in German patients with type 2 diabetes.
The disease's growing incidence, prevalence, and progressive nature have encouraged the development of new drugs to provide additional treatment options for dietic patients. Non-insulin treatments, used as first-line therapies for patients who have diabetes, currently capture more than half the sales in the anti-diabetics market. German law requires public plans to cap out-of-pocket health care costs and to cover all medically necessary treatment, including insulin. Germany is one of the developed countries with advanced healthcare facilities. Moreover, reimbursement and pricing policies are highly regulated, which drives the market.
The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among people are some market opportunities for the players in the German diabetes drugs market.
Get Analysis on Important Geographic Markets
Download PDF
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Industry Overview
The Europe GLP-1 market is consolidated, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, etc., holding a presence in the region.
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Leaders
-
Novo Nordisk
-
AstraZeneca
-
Eli lilly and Company
-
Sanofi
-
Pfizer
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market News
- April 2023: Eli Lilly and Company and Amphastar Pharmaceuticals, Inc. entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product. BAQSIMI is the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes. Amphastar expects to provide dedicated commercial investment for BAQSIMI with the goal of enabling more people on insulin to be prepared with a glucagon rescue treatment for severe hypoglycemia.
- March 2023: NHS approved Wegovy, a weight loss injection also known as semaglutide. Wegovy mimics the hormone glucagon-like peptide-1 (GLP-1) and suppresses appetite.
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Industry Segmentation
GLP-1 receptor agonists are a non-insulin medication used in combination with diet and exercise to help treat type 2 diabetes. The Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market is segmented into drugs (Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide), brands (Byetta, Bydureon, Victoza, Trulicity, Lyxumia, and Ozempic) and Geography (Germany, Spain, Italy, France, United Kingdom, Russia, and Rest of Europe). The report offers the value (in USD million) and volume (in Units million) for the above segments. Further, the report will cover a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents.
| Drug | Exenatide | Byetta | |
| Bydureon | |||
| Liraglutide | Victoza | ||
| Lixisenatide | Lyxumia | ||
| Dulaglutide | Trulicity | ||
| Semaglutide | Ozempic | ||
| Geography | Germany | ||
| Spain | |||
| Italy | |||
| France | |||
| United Kingdom | |||
| Russia | |||
| Rest of Europe | |||
Need A Different Region or Segment?
Customize Now
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Research FAQs
How big is the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market?
The Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size is expected to reach USD 4.17 billion in 2025 and grow at a CAGR of 5.90% to reach USD 5.56 billion by 2030.
What is the current Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size?
In 2025, the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size is expected to reach USD 4.17 billion.
Who are the key players in Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market?
Novo Nordisk, AstraZeneca, Eli lilly and Company, Sanofi and Pfizer are the major companies operating in the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market.
What years does this Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market cover, and what was the market size in 2024?
In 2024, the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size was estimated at USD 3.92 billion. The report covers the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Europe GLP-1 Agonists Industry Report
Statistics for the 2025 Europe Glucagon-Like Peptide-1 (GLP-1) Agonists market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Glucagon-Like Peptide-1 (GLP-1) Agonists analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
